SAHPRA + research peptides — South Africa's pharmaceutical-import framework

SAHPRA assumed the roles of the Medicines Control Council and the Directorate of Radiation Control, previously housed at the National Department of Health; its mandate is set out in the Medicines and Related Substances Act 101 of 1965 (as amended) and the Hazardous Substances Act 15 of 1973. SAHPRA registers and regulates medicines, medical devices, and complementary medicines in South Africa. The Act lists controlled substances in Schedules: a Schedule 0 substance may be sold in an open shop, while importing or exporting a specified Schedule 5 to Schedule 8 substance requires a permit from the Director-General (Medicines and Related Substances Act, s22A). Section 14 of the Act prohibits the sale of any medicine that is subject to registration unless it is registered — research peptides sold without SAHPRA registration fall on the wrong side of that rule.

Section 21 of the Act is not a research exemption. It lets SAHPRA authorise a named person to sell, for a specified period, a specified quantity of an unregistered medicine to a specified person or institution, and SAHPRA's Section 21 unit processes applications from treating practitioners for access to unregistered medicines (Category A medicines for human use; separate procedures exist for unregistered veterinary and complementary medicines). Institutional research with an unregistered compound therefore runs through a SAHPRA authorisation plus the institution's own ethics approval, not through an open research-use carve-out.

For research-use-only substances sold as research chemicals — the peptide vendor model — Section 14 makes no exception for a "for laboratory research, not for human use" label, and SAHPRA's public notice on peptide products (May 2026) says unregistered peptide products are sold unlawfully through online platforms, social media, gyms and wellness centres, and informal suppliers, without approval under the Act. There is no research-use carve-out for vendors, and none for individual buyers: SAHPRA's import guideline states that no person shall order any medicine from abroad for personal use without a Section 21 authorisation.

BPC-157 in South Africa: SAHPRA's May 2026 notice lists BPC-157 first among its examples of illegally marketed peptides, alongside TB-500, Melanotan II, CJC-1295, Ipamorelin, PT-141, AOD-9604, Selank and Semax. No BPC-157 product appears in SAHPRA's register of registered health products (searched 7 October 2026), and the consolidated Schedules of 1 August 2025 do not name it — which does not make it an approved product. A Section 21 authorisation, SAHPRA's route to an unregistered medicine for a specified person, is subject to confirmation from a medical professional that the product is needed and that no similar product is available in the country. For tested athletes, BPC-157 is prohibited at all times under S0 of the WADA Prohibited List.

Reschem — an SA-domestic vendor — ships within South Africa with HPLC + LC-MS COAs, ZAR pricing and 1–3 day domestic delivery, under research-use-only labelling. Domestic shipping removes customs friction; it does not change the registration position SAHPRA set out in its May 2026 notice, which is why the Reschem record on this site carries a SAHPRA warning.

For other African countries (Nigeria, Kenya, Egypt, etc.), the SA-domestic option doesn't apply — Reschem's published shipping policy lists only South African delivery. Shipments from international vendors rely on courier partnerships (DHL is most common) and face country-specific customs frameworks (covered in the country-specific articles below).

For SA institutional researchers, a Section 21 authorisation is the formal route to an unregistered compound, and SAHPRA runs a border-control process for importing medical products under the Act. Researchers in academic positions should use institutional procurement before considering personal-purchase routes.

On WADA / sport-doping side, SAIDS (South African Institute for Drug-Free Sport) is WADA-aligned and tests SA athletes in the standard WADA framework. Research peptides prohibited under S0; BPC-157 named explicitly since 2022. Cricket South Africa, SAFA (soccer), and SARU (rugby) have all sanctioned peptide-positive players. For tested SA athletes, WADA framework rules apply.

More from this region.

Other articles covering this region's vendors, regulatory framework, and research peptides.

• 2026-10-08Earlier versions said research-class shipments from international vendors typically clear South African customs in 5–10 business days. PeptideGuide holds no clearance data; the figure was removed.
• 2026-10-07Earlier versions described South Africa as more permissive than other frameworks, with individual buyers in a "grey zone" and minimal enforcement. SAHPRA's May 2026 public notice lists BPC-157 and other research peptides as illegally marketed, and its import guideline requires a Section 21 authorisation for personal orders from abroad. The text was corrected and a BPC-157 section was added with official sources.
• 2026-10-06Earlier versions described Section 21 of the Medicines and Related Substances Act as a research-use exemption and the scheduling framework as Schedules 1 through 7. Section 21 is an authorisation to sell a specified quantity of an unregistered medicine to a specified person or institution (applications are handled for treating practitioners), and substances are scheduled from Schedule 0 upwards. The text was corrected and official SAHPRA sources were linked.